タキザワ　マキコ   TAKIZAWA Makiko   滝沢　牧子    所属   埼玉医科大学  医学部 総合医療センター　医療安全管理学    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.
掲載誌名	正式名：International journal of hematology
掲載区分	国内
巻・号・頁	111(6),812-825頁
著者・共著者	Masatoshi Sakurai,Shinichiro Okamoto,Itaru Matsumura,Satsuki Murakami,Makiko Takizawa,Masato Waki,Daiki Hirano,Reiko Watanabe-Nakaseko,Naoki Kobayashi,Masaki Iino,Hideki Mitsui,Yuichi Ishikawa,Naoto Takahashi,Tatsuya Kawaguchi,Ritsuro Suzuki,Kazuhito Yamamoto,Masahiro Kizaki,Kazunori Ohnishi,Tomoki Naoe,Koichi Akashi
発行年月	2020/06
概要	We herein report the results of the New TARGET study 2nd-line, which collected data on patients with chronic-phase (CP) chronic myeloid leukemia (CML) who received a 2nd-line tyrosine kinase inhibitor (TKI) because of resistance and/or to a 1st-line TKI. A total of 98 patients were enrolled intolerance between April 2010 and March 2013, and 82 patients were analyzed. The median age was 54 years (range 22-88 years). Seventy-six patients (93%) received imatinib as the 1st-line TKI. Forty-five (55%) and 37 (45%) patients began nilotinib and dasatinib treatments at entry, respectively. First-line TKI treatment achieved complete hematological response in 79 patients (96%) and complete cytogenetic response (CCyR) in 49 patients (60%), respectively. Nine patients (11%) had BCR-ABL1 kinase domain point mutations at enrollment. The estimated 3-year progression-free-survival rate after enrollment was 98.7% (95% CI 91.1-99.8%). Overall, the probabilities of achieving CCyR and a major molecular response were 89.3% (95% CI 81.4-94.8%) and 87.2% (95% CI 78.1-93.8%), respectively. There were no new safety issues. This study demonstrated that CML-CP patients in Japan who are resistant and/or intolerant to a 1st-line TKI can achieve an extremely good outcome by 2nd-line TKI treatment.
DOI	10.1007/s12185-020-02843-8
PMID	32152876